ETHNOBOTANICAL BASED ANTI-RSV THERAPEUTICS

呼吸道合胞病毒(RSV)可引起婴儿、幼儿和成人的毛细支气管炎和肺炎等下呼吸道感染。在缺乏有效的疫苗和较少争议的化合物来预防或改善RSV感染的情况下，RSV仍然是一个严重的健康威胁，必须持续努力寻找更有效的新制剂。我们已经确定了一种民族植物(EB)制剂(ZX-2187P)，它具有显著的抗RSV活性。这项应用的总体范围是调查这种EB制剂作为控制RSV感染的治疗药物的潜力。具体目的包括利用体外试验系统评价ZX-2187P对多种RSV株的体外抗RSV活性，进行ZX-2187P的体内抗RSV活性评价，通过实验阐明ZX-2187P的作用机理(S)，并对ZX-2187P进行提取、分离和纯化以鉴定纯化合物(S)。拟议的商业应用：RSV是婴幼儿的主要病毒病原体，是成人疾病的重要原因，并对老年人的发病率和死亡率负责。目前还没有疫苗，而且批准使用的利巴韦林和免疫球蛋白的组合昂贵且难以管理。因此，任何能够控制呼吸道合胞病毒感染的新制剂(S)都会产生巨大的经济影响。

Respiratory syncytial virus (RSV) causes lower respiratory tract infections such as bronchiolitis and pneumonia in infants, young children and adults. In the absence of an effective vaccine and less controversial compounds to prevent or ameliorate RSV infections, RSV remains a serious health threat and a sustained effort must be mounted to find new agents with enhanced efficacy. We have identified an Ethnobotanical (EB) preparation (ZX-2187P) that shows significant anti-RSV activity. The overall scope of this application is to investigate the potential of this EB preparation as a therapeutic for controlling RSV infections. The specific aims include, evaluation of anti-RSV activity of ZX-2187P against multiple RSV strains in multiple cell lines using in vitro assay systems, performing in vivo anti-RSV evaluation of ZX-2187P, conducting experiments to elucidate the mechanism(s) of action of ZX-2187P and performing extraction, fractionation and purification of ZX-2187P to identify pure compound(s). PROPOSED COMMERCIAL APPLICATIONS: RSV is a major virus pathogen of infants and young children, an important cause of disease in adults and is responsible for a significant amount of morbidity and mortality in the elderly. No vaccines are available and the combination of ribavirin and immunoglobulin approved for use is expensive and difficult to administer. Thus, any new agent(s), which can control RSV infection, has a huge economical impact.